Skip to content
MARKETS / NASDAQ / QTEX
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Qtrex Quantum Ltd. QTEX

5 fiscal years on record · USD · FY2025 reported · SEC filings only
$289,000
$-13.2M
$-10.0M
In brief

What this company does

We are a specialty medical device company the research, development, manufacturing, and commercialization of proprietary life support technologies. We aim for our technology to supersede and revolutionize the global mechanical ventilation market. The INSPIRA ART100 system utilizes a technique that circulated the patient’s blood, adding oxygen to the blood and removes carbon dioxide, with the enriched blood being circulated back to the patient, taking over the functionality of the heart and/or lungs in critical care patients undergoing life-saving procedures. The INSPIRA ART100 has received FDA 510(k) regulatory clearance for use in an extracorporeal perfusion circuit to pump blood during short-duration cardiopulmonary bypass procedures lasting 6 hours or less. Our goal is to support healthcare systems by providing a practical and portable solution facilitating the treatment of respiratory failure, without the need for mechanical ventilation, and with the ability to deploy INSPIRA ART systems in and outside of ICUs to an ambulatory treatment that can be administered in all hospital wards as well as in ambulances.

Written from the business description in QTREX Quantum Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 26 March 2026. Every sentence was checked against that document before publication.

Growth
USD 289,000.00
Revenue, FY2025 · full 5-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.3 · Net income -13.2
-5M-10M20212022202320242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−4574 cents
lost on every revenue dollar
ROE
FY2025 · ROE -397.9%
-100%-200%-300%20212022202320242025

Each USD of equity lost 398 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -10.0
-4M-8M20212022202320242025

Total assetsUSD 5.3M
EquityUSD 2.3M
CashUSD 3.2M
Current ratio1.56×

Equity funds 43% of total assets.

The 5-year record
5 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021
Revenue $B0.00.00.0··
Operating income $B−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.0··
Net income $B−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.45−0.60−0.93−1.39−3.24
Dividend / sh $·····
Payout %·····
ROE %−397.9−219.7−116.5−80.2−153.5
Shares out B0.040.020.020.01·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 22 reconciliationsAUDITED

Reconciled in 6 of 19 fiscal years. 73 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inoutside the United States — SEC code L3
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2020

Share this section

Download image